Become a member

Expert Insight Series: TYPE 2 DIABETES – An Alternative Perspective

Expertise by Bilateral Chamber Member: PureLife Health Sciences Group

WORLDWIDE 2017 –The rising impact of diabetes has a potentially devastating effect toll upon future generations and worldwide economies. Hence, there is a need for immediate action to help prevent and possibly reverse diabetes for those at risk and those who have the disease. Preventing and providing care for diabetes requires improvements to our health care systems and having alternative treatment options available.

Type 2 Diabetes Mellitus is growing rapidly in developing countries and is projected to be the most challenging and costly health problem facing the world in the next 25 years. However, a vast number of people with diabetes are going undiagnosed until they are faced with more serious complications.

FUTURE: The population of people with diabetes is expected to increase by 65% by 2025. Since treatments for diabetes is the most expensive disease to treat long term, this will result in significantly higher total health expenditures worldwide, especially the Middle East region. The diabetes epidemic is driven by several factors, including high blood pressure, abnormal cholesterol and high triglycerides, obesity and lack of physical activities.

COMPLICATIONS ASSOCIATED WITH DIABETES: These health issues drive the costs of treating Diabetes:

– Heart Disease – At least 68% of people age 65 or older with diabetes die from some form of heart disease.

– Kidney Failure – Urine testing and regular blood pressure checkups to monitor and control high blood pressure helps delay the onset of kidney disease.

– Retinopathy (eye disease) – Eye disease or symptoms of blurred vision in addition to diabetes is a leading cause of blindness and visual disability. Metabolic control can delay the onset and progression of retinopathy.

– Neuropathy – Numbness or tingling in feet is a sign of nerve disease that may lead to sensory loss and damage to limbs. It is the most common complication of Diabetes. Half of the population of diabetics are affected.

RISKS OF INTENSIVE TREATMENT METHODS: The risks of treating diabetes with intensive glucose lowering treatment drugs may be far worse than the disease. * According to recently published research, intakes of a combination of diabetic drugs simultaneously may increase your risk of death. A new meta-analysis of 13 randomized controlled trials involving more than 34,000 people showed that intensive treatment methods is not only ineffective but may be dangerous as well. Intensive treatment with glucose lowering drugs actually showed the potential to increase your risk of death from heart-related, and all other causes.

*RESEARCHERS NOTED: “The overall results of the meta-analysis do not show a benefit of intensive glucose lowering treatment on all-cause mortality or cardiovascular death. A 19% increase in all-cause mortality and a 43% increase in cardiovascular mortality cannot be excluded.”

SOLUTIONS: Since type 2 diabetes prevention and treatments include careful monitoring of food intake (quantity and quality) with the addition of physical activity, alternative treatments are necessary for people to adapt in order to fit their lifestyle. The growth of the diabetes epidemic can be controlled by changing the environment in which people make lifestyle decisions, along with greater public awareness of the top risk factors for the disease. The solution currently exists, we have to make the choice to act today!


John Payne is Chairman & CEO of PureLife Health Sciences Group, LLC and heads a team of scientific researchers and doctors specializing in the treatment and reversal of Diabetes and Metabolic Syndrome health disorders and its myriad of critical health issues. As a therapeutic solutions provider, PureLife focuses on the development of plant based nutraceuticals sourced from traditional food sources that effect nutrigenomic activity, nutrient gene interactions, and epigenetics.


*The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Bilateral US-Arab Chamber of Commerce.